SCHEMBL5826261

SCHEMBL5826261

O=C(CCN1C(=O)C=CC1=O)OCCO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 7/20 0.46
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
BLM P54132 1/20 0.44
WRN Q14191 1/20 0.44
HIF1A Q16665 1/20 0.44
PTGS1 P23219 7/20 0.43
PTGS2 P35354 7/20 0.43
GSK3A P49840 2/20 0.43
GSK3B P49841 2/20 0.43
FAAH O00519 3/20 0.42
MAPK1 P28482 2/20 0.41
MAPT P10636 2/20 0.41
RECQL P46063 2/20 0.41
HSP90AA1 P07900 1/20 0.41
TLR9 Q9NR96 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7098396 0.91 MGLL (0.50) MGLLALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL14984834 0.87 PTGS1 (0.49) MGLLALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL2111408 0.87 PTGS1 (0.58) MGLLALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL14014722 0.84 MGLL (0.39) MGLLALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL12021170 0.84 MGLL (0.44) MGLLALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL5160607 0.84 ALDH1A1 (0.51) MGLLALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL3874763 0.83 ALDH1A1 (0.63) MGLLALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL14014719 0.83 MGLL (0.43) MGLLALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL20637068 0.81 GSK3A (0.65) MGLLALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL5166306 0.81 MAPK1 (0.58) MGLLALDH1A1HPGDCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10774181-B2 N-maleimidyl polymer derivatives NEKTAR THERAPEUTICS (US) 2020-09-15 US disclosed
US-20190330422-A1 N-MALEIMIDYL POLYMER DERIVATIVES NEKTAR THERAPEUTICS 2019-10-31 US disclosed
US-10385165-B2 N-maleimidyl polymer derivatives NEKTAR THERAPEUTICS (US) 2019-08-20 US disclosed
US-20180051135-A1 N-MALEIMIDYL POLYMER DERIVATIVES NEKTAR THERAPEUTICS 2018-02-22 US disclosed
US-9828465-B2 N-maleimidyl polymer derivatives NEKTAR THERAPEUTICS (US) 2017-11-28 US disclosed
US-20170088668-A1 N-MALEIMIDYL POLYMER DERIVATIVES NEKTAR THERAPEUTICS 2017-03-30 US disclosed
US-9493609-B2 N-maleimidyl polymer derivatives NEKTAR THERAPEUTICS (US) 2016-11-15 US disclosed
US-20160083514-A1 N-MALEIMIDYL POLYMER DERIVATIVES NEKTAR THERAPEUTICS 2016-03-24 US disclosed
US-9169350-B2 N-maleimidyl polymer derivatives NEKTAR THERAPEUTICS (US) 2015-10-27 US disclosed
US-20150166725-A1 N-Maleimidyl Polymer Derivatives NEKTAR THERAPEUTICS (US) 2015-06-18 US disclosed
US-8992902-B2 N-maleimidyl polymer derivatives NEKTAR THERAPEUTICS (US) 2015-03-31 US disclosed
US-20140256957-A1 N-Maleimidyl Polymer Derivatives NEKTAR THERAPEUTICS (US) 2014-09-11 US disclosed
US-8454946-B2 N-maleimidyl polymer derivatives NEKTAR THERAPEUTICS (US) 2013-06-04 US disclosed
US-20060013797-A1 N-maleimidyl polymer derivatives NEKTAR THERAPEUTICS 2006-01-19 US disclosed
US-6602498-B2 Water soluble polymer backbone such as polyethylene glycol, endcapped with a N-maleimidyl moiety without using a linker; conjugated peptides, proteins, nucleotides and drugs SHEARWATER CORPORATION 2003-08-05 US disclosed
US-20010044526-A1 Water soluble polymer backbone such as polyethylene glycol, endcapped with a N-maleimidyl moiety without using a linker; conjugated peptides, proteins, nucleotides and drugs SHEARWATER CORPORATION 2001-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170088668-A1 N-MALEIMIDYL POLYMER DERIVATIVES NGLY1, PIN1, NMT2 MGLL 2444/4885ALDH1A1 4566/4885HPGD 1009/4885
US-10385165-B2 N-maleimidyl polymer derivatives NGLY1, PIN1, NMT2 MGLL 2444/4885ALDH1A1 4566/4885HPGD 1009/4885
US-20190330422-A1 N-MALEIMIDYL POLYMER DERIVATIVES NGLY1, PIN1, NMT2 MGLL 2444/4885ALDH1A1 4566/4885HPGD 1009/4885
US-10774181-B2 N-maleimidyl polymer derivatives NGLY1, PIN1, NMT2 MGLL 2444/4885ALDH1A1 4566/4885HPGD 1009/4885
US-20180051135-A1 N-MALEIMIDYL POLYMER DERIVATIVES NGLY1, PIN1, NMT2 MGLL 2444/4885ALDH1A1 4566/4885HPGD 1009/4885
US-20060013797-A1 N-maleimidyl polymer derivatives NGLY1, PIN1, NMT2 MGLL 2444/4885ALDH1A1 4566/4885HPGD 1009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.